Michel Reijnen (Arnhem, Netherlands) talks to Vascular News about the four-year IN.PACT Global study results, focusing on the 156 patients in the study who had critical limb ischaemia (CLI). These patients had a mean lesion length of 40 centimetres and 77% of them had calcifications.
Reijnen discusses the benefits of using drug-coated balloons in such a complex set of patients and notes that the frailty of these patients is shown by the fact that at four-year follow-up more than 30% of the cohort had died. The study findings indicated that the DCB is “safe and effective” in this CLI sub-group, with clinically-driven target lesion revascularisation (TLR) of 65% and a “remarkably high” limb salvage rate of 97% at four years.
